In the CHER-LOB trial, which involved neoadjuvant therapy for HER2-positive breast cancer, patients with the FcγR3A 559T>G who received trastuzumab plus lapatinib demonstrated a significantly higher pathological complete response (pCR) rate compared to those receiving trastuzumab or lapatinib alone [128]. Here, ERBB2 is linked to breast cancer.